Clinical Trials Logo

Subjective Cognitive Decline clinical trials

View clinical trials related to Subjective Cognitive Decline.

Filter by:

NCT ID: NCT06358404 Not yet recruiting - Clinical trials for Subjective Cognitive Decline

Developing a Peer Support Intervention for Depression in SCD

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the feasibility, acceptability, and fidelity of an 8-week intervention where peer coaches will deliver depression care to adults 60 years of age or older who have depression and subjective cognitive decline.

NCT ID: NCT06335836 Recruiting - Alzheimer Disease Clinical Trials

The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)

Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD 1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD; 2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation; 3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions; 4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.

NCT ID: NCT06287489 Recruiting - Clinical trials for Subjective Cognitive Decline

Effects of Mediterranean Diet on Subjective Cognitive Decline

Start date: October 26, 2023
Phase: N/A
Study type: Interventional

Research Questions: 1. Due to the fact that most participants in past clinical trials on the Mediterranean diet were cognitively healthy individuals, and while the observed effects were significant, they were not particularly substantial, does the Mediterranean diet have similarly significant and more pronounced effects on both physical and cognitive functions in older adults with subjective cognitive decline (SCD)? 2. What is the mechanism behind the effects of the Mediterranean diet on physical or/and cognitive function? Is it through vascular protection or improvements in brain structure/brain network function? Research Objective: Conduct a cross-over randomized controlled trial to investigate the effects of a three-month Mediterranean diet on the physical and cognitive functions of older adults with subjective cognitive decline (SCD) in the community. Utilize brain MRI and circulatory biomarkers measurements to elucidate the underlying mechanisms.

NCT ID: NCT06281652 Recruiting - Clinical trials for Mild Cognitive Impairment

Cognitive Intervention With Go and Chess in Early and Subjective Cognitive Decline

Cognichess
Start date: February 13, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial]is to evaluate if learning to play traditional board games could improve cognition in subjects with mild cognitive impairment and subjective cognitive decline. The main questions it aims to answer are: - Do Go and Chess improve cognition? - Is a game better than the other? Is the effect of both games on cognition synergistic? - Do Go and Chess improve quality of life? - Do Go and Chess improve mood? - Do Go and Chess improve lifestyle? Participants will be randomized to one of four groups: - Group intervention with Go, once a week, for 12 weeks - Group intervention with Chess, once a week, for 12 weeks - Group intervention with Go and Chess, twice a week, for 12 weeks - Control group

NCT ID: NCT06191952 Recruiting - Alzheimer Dementia Clinical Trials

Davos Alzheimer's Collaborative Healthcare System Preparedness to Increase Cognitive Assessment Rates for Older Adults

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

In this study the investigators explore a pragmatic strategy to increase cognitive screening rates in the community. The investigators will compare the monetary value of different combinations of SCD questionnaires, digital cognitive tests, and blood Alzheimer's Disease (AD) biomarkers to identify the best approach for primary care settings.

NCT ID: NCT06110858 Recruiting - Clinical trials for Subjective Cognitive Decline

Efficacy of Tinkering Activities in Individuals With Subjective Cognitive Decline

Start date: November 13, 2023
Phase: N/A
Study type: Interventional

Given that preventing and delaying the onset of dementia is a crucial public health policy issues worldwide, it is essential to develop effective interventions and implement early interventions before the onset of dementia. Subjective Cognitive Decline (SCD) is considered the earliest manifestation of dementia and individuals with SCD may have a higher risk for future cognitive decline and dementia. Despite performing normally on objective cognitive tests, individuals with SCD have been found to exhibit worse performance on some cognitive domains, including executive functions, compared to those without SCD. Executive Functions (EFs) refer to a set of cognitive processes that include working memory, inhibition, cognitive flexibility, planning, problem solving and reasoning, enabling individuals to achieve goals by controlling and regulating thoughts and behaviors. EFs are important for our daily functioning and their decline can negatively impact an individual's quality of life. However, to our knowledge, there is limited research on maintaining or improving EFs in individuals with SCD. Tinkering Activity (TA) is a hands-on cognitive activity that emphasizes process of problem-solving, active engagement and open-ended exploration, which challenges EFs. In addition, previous research has shown the benefits of TA for community-dwelling older adults. Therefore, the goal of this clinical tri is to examine the efficacy of TA based cognitive intervention in enhancing EFs in individuals with SCD. This study will be a one-group pretest-posttest design. Twelve to fifteen individuals with SCD will be recruited from the communities. All participants will receive 12 intervention sessions, each lasting 2 hours, with two sessions per week for 6 weeks. All participants will be assessed before and after the intervention.

NCT ID: NCT06095063 Recruiting - Alzheimer Disease Clinical Trials

dTMS for Subjective Cognitive Decline

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

Deep transcranial magnetic stimulation (dTMS) is a brain stimulation technique that involves generating a brief magnetic field in a coil that is placed on the scalp. The magnetic field passes through the skull and induces a weak electrical current in the brain that briefly activates neural circuits at the stimulation site. The Brainsway dTMS H7-Coil is able to target an area of the brain that has been shown in studies to be linked to greater resilience to cognitive decline. In this study, the investigators will combine dTMS with cognitive training in older adults with subjective cognitive decline (SCD) and examine the effect of this treatment on memory, other cognitive abilities, and mood. In addition, the investigators will examine the combined effects of dTMS and cognitive training on brain activity as measured using electroencephalography (EEG). Approximately 30 older adults from ages 55 to 70 with SCD and a positive family history of Alzheimer's disease will be enrolled in this study.

NCT ID: NCT06078748 Recruiting - Clinical trials for Subjective Cognitive Decline

The Lifestyle Exercise and Diet Trial (LEAD) 2.0

Start date: October 3, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to investigate the feasibility of a virtually-delivered 6-month exercise and nutrition intervention in older adults with executive subjective cognitive decline (SCD). Feasibility will be determined by recruitment, retention, and adherence rates. Preliminary changes in cognition, physical function, and quality of life will be assessed as secondary outcomes. The study will recruit 140 participants aged 65 to 80 who report they feel that their memory or other thinking abilities are declining. Participants will be randomized into one of four study arms receiving different combinations of healthy lifestyle interventions. Assessments will be conducted virtually at baseline, post-intervention (6 months), and follow-up (12 months). All intervention sessions and assessment visits will be conducted online using the Zoom Healthcare platform and participants will log on using their own devices from home.

NCT ID: NCT06002477 Not yet recruiting - Clinical trials for Subjective Cognitive Decline

Attentional Mechanisms in SCD

AMoCC-SCD
Start date: June 1, 2024
Phase: Early Phase 1
Study type: Interventional

This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.

NCT ID: NCT05756270 Recruiting - Clinical trials for Mild Cognitive Impairment

Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients

CAPE
Start date: June 3, 2022
Phase:
Study type: Observational

The goal of this observational study is to compare cerebral perfusion patterns with pseudo-continuous arterial spin labeling (pCASL) and brain metabolism patterns with fluorodeoxyglucose-position emission tomography (FDG-PET) in patients with mild cognitive impairment (MCI) and subjective cognitive decline (SCD). The main questions it aims to answer are: - Do pCASL sequences identify hypoperfusion patterns that correlate well with FDG-PET hypometabolic patterns? - Are there differences in this correlation in terms of cerebrospinal fluid (CSF) profiles? - Can hypoperfusion patterns in pCASL predict conversion to dementia? Participants will undergo brain 3 Tesla magnetic resonance imaging (MRI), FDG-PET, lumbal puncture and blood collection to analyze amyloid beta and tau, yearly detailed neuropsychological tests for three years.